Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia

AI Briefing

• – Aplagon announces dosing of first patient in Phase 2a clinical trial of APAC in PAOD/CLTI.
• – APAC is a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects.
• – Aplagon is pioneering a treatment for thrombo-inflammatory diseases.